Westover Capital Advisors LLC Sells 9,053 Shares of Sanofi (NASDAQ:SNY)

Westover Capital Advisors LLC decreased its position in Sanofi (NASDAQ:SNY) by 59.3% in the 4th quarter, HoldingsChannel reports. The fund owned 6,226 shares of the company’s stock after selling 9,053 shares during the period. Westover Capital Advisors LLC’s holdings in Sanofi were worth $310,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. McIlrath & Eck LLC raised its stake in shares of Sanofi by 143.3% in the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after purchasing an additional 361 shares in the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Sanofi by 24.5% during the 4th quarter. Hexagon Capital Partners LLC now owns 4,993 shares of the company’s stock worth $248,000 after acquiring an additional 984 shares during the period. Altrius Capital Management Inc boosted its position in shares of Sanofi by 1.7% during the 4th quarter. Altrius Capital Management Inc now owns 135,311 shares of the company’s stock valued at $6,729,000 after acquiring an additional 2,318 shares in the last quarter. Transcend Capital Advisors LLC raised its position in Sanofi by 5.7% in the fourth quarter. Transcend Capital Advisors LLC now owns 5,730 shares of the company’s stock worth $285,000 after purchasing an additional 307 shares in the last quarter. Finally, Unique Wealth Strategies LLC bought a new position in Sanofi during the fourth quarter worth about $577,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

SNY stock traded down $0.45 during midday trading on Friday, reaching $49.01. 1,113,911 shares of the company’s stock traded hands, compared to its average volume of 2,036,891. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a market cap of $123.98 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 1.39 and a beta of 0.61. The company has a 50-day simple moving average of $47.89 and a two-hundred day simple moving average of $48.27. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.93.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. On average, analysts anticipate that Sanofi will post 4.12 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is currently 69.35%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SNY shares. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley started coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.